Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Phosphoenolpyruvate carboxykinase (PEPCK) deficiency is a gluconeogenesis disorder that results from impairment in the enzyme PEPCK, and comprising cytosolic (PEPCK1) and mitochondrial (PEPCK2) forms of enzyme deficiency. Onset of symptoms is neonatal or a few months after birth and includes hypoglycemia associated with acute episodes of severe lactic acidosis, progressive neurological deterioration, severe liver failure, renal tubular acidosis and Fanconi syndrome. Patients also present progressive multisystem damage with failure to thrive, muscular weakness and hypotonia, developmental delay with seizures, spasticity, lethargy, microcephaly and cardiomyopathy. To date, there is no conclusive evidence of the existence of an isolated form of this disorder.
Features include very common findings: Recurrent hypoglycemia; and common findings: Increased circulating lactate concentration, Hypoglycemic seizures, Lactic acidosis, and Hyperglutaminemia and others. 22 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 4 | Increased circulating lactate concentration, Increased urine alpha-ketoglutarate concentration, Elevated circulating aspartate aminotransferase concentration |
Phenotype severity distribution: 1 very common feature, 9 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for phosphoenolpyruvate carboxykinase deficiency.
8 publications have been identified in PubMed for phosphoenolpyruvate carboxykinase deficiency. Research spans Basic Science / Preclinical (50%), Case Report / Case Series (38%), and Review / Meta-Analysis (13%).
Novoa E (2026). [PMID: 41734768](https://pubmed.ncbi.nlm.nih.gov/41734768/). *Cell Metab*. [Basic Science / Preclinical]
Vasiļevska L (2026). [PMID: 41608521](https://pubmed.ncbi.nlm.nih.gov/41608521/). *JIMD Rep*. [Case Report / Case Series]
Lei Y (2026). [PMID: 41910356](https://pubmed.ncbi.nlm.nih.gov/41910356/). *Aging Cell*. [Basic Science / Preclinical]
Bernhardt I (2026). [PMID: 41549939](https://pubmed.ncbi.nlm.nih.gov/41549939/). *Am J Med Genet A*. [Case Report / Case Series]
Burg D (2025). [PMID: 40092582](https://pubmed.ncbi.nlm.nih.gov/40092582/). *Mol Genet Metab Rep*. [Case Report / Case Series]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:02 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Digestive system | 3 | Hepatic steatosis, Decreased liver function, Vomiting |
Brain and nerves | 2 | Hypoglycemic seizures, Acute encephalopathy |
Head and neck | 1 | Microcephaly |
Muscles | 1 | Low muscle tone (hypotonia) |
Pregnancy and birth | 1 | Neonatal hypoglycemia |
Dalga D (2025). [PMID: 40645291](https://pubmed.ncbi.nlm.nih.gov/40645291/). *Kidney Int*. [Basic Science / Preclinical]
Sullivan MA (2025). [PMID: 41110885](https://pubmed.ncbi.nlm.nih.gov/41110885/). *Kidney Int*. [Basic Science / Preclinical]